stop term
study
model
increase
decrease
small
large
reduction
high
low
dose
patient
treatment
decline
hypothesis
drug
empagliflozin
dapagliflozin
canagliflozin
placebo
clinical
trial
study
group
baseline
population
base
therapy
regression
sglt
type
diabetes
dm
inhibitor
inhibition
relationship
correlation
rct
cohort
day
risk
year
long
term
associate
positive
negative
evidence
agent
clinician
potential
mechanism
trail
effect
diabetic
diabete
week
event
support
association
meta
analysis
glm
japanese
function
disease
level
empa
canvas
reg
outcome
reduce
database
participant
review
report
